JNJ

186.77

-1.86%↓

ABT

126.59

-0.44%↓

TMO

557.87

-1.14%↓

ISRG

545.39

-0.79%↓

DHR

216.84

-1.92%↓

JNJ

186.77

-1.86%↓

ABT

126.59

-0.44%↓

TMO

557.87

-1.14%↓

ISRG

545.39

-0.79%↓

DHR

216.84

-1.92%↓

JNJ

186.77

-1.86%↓

ABT

126.59

-0.44%↓

TMO

557.87

-1.14%↓

ISRG

545.39

-0.79%↓

DHR

216.84

-1.92%↓

JNJ

186.77

-1.86%↓

ABT

126.59

-0.44%↓

TMO

557.87

-1.14%↓

ISRG

545.39

-0.79%↓

DHR

216.84

-1.92%↓

JNJ

186.77

-1.86%↓

ABT

126.59

-0.44%↓

TMO

557.87

-1.14%↓

ISRG

545.39

-0.79%↓

DHR

216.84

-1.92%↓

Search

Codexis Inc

Cerrado

SectorSanidad

2.59

Resumen

Variación precio

24h

Actual

Mínimo

2.54

Máximo

2.73

Métricas clave

By Trading Economics

Ingresos

7.4M

-13M

Ventas

7.8M

15M

BPA

-0.16

Margen de beneficios

-86.587

Empleados

188

EBITDA

7.6M

-13M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+143.46% upside

Dividendos

By Dow Jones

Próximas Ganancias

6 nov 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

15M

247M

Apertura anterior

2.59

Cierre anterior

2.59

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

154 / 373 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Bullish Evidence

Codexis Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

28 oct 2025, 23:50 UTC

Acciones populares

Stocks to Watch: Caesars, Enphase, Mondelez, Teradyne

28 oct 2025, 23:25 UTC

Ganancias

SK Hynix Posts Record Earnings on Continued AI-Chip Demand

28 oct 2025, 23:18 UTC

Ganancias

Booking 3Q Sales Rise as U.S. Travel Demand Stabilizes -- Update

28 oct 2025, 22:20 UTC

Ganancias

Visa Sales Jump as Consumers Keep Spending -- 2nd Update

28 oct 2025, 22:13 UTC

Ganancias

Wal-Mart de Mexico Net Profit Falls in 3Q

28 oct 2025, 21:38 UTC

Ganancias

Correction to Visa Sales Jump Article

28 oct 2025, 21:17 UTC

Ganancias

OrthoPediatrics Wins FDA Approval for Surgery Plating System; 3Q Revenue Rises

28 oct 2025, 21:07 UTC

Ganancias

Visa Sales Jump as Consumers Keep Spending -- Update

28 oct 2025, 21:02 UTC

Ganancias

Mondelez Tempers Outlook as Costs Rise

28 oct 2025, 23:51 UTC

Charlas de Mercado

Nikkei May Rise on Easing U.S.-China Tensions -- Market Talk

28 oct 2025, 23:42 UTC

Charlas de Mercado

Gold Edges Lower on Possible Position Adjustments Ahead of FOMC Decision -- Market Talk

28 oct 2025, 23:02 UTC

Ganancias

SK Hynix: HBM4 Shipments to Start in 4Q, Ahead of Full-Scale Sales Expansion in 2026

28 oct 2025, 23:01 UTC

Ganancias

SK Hynix: Completed Discussions With Key Customers About 2026 HMB Supply

28 oct 2025, 22:46 UTC

Ganancias

SK Hynix: Co. Secured Full Customer Demand for Its Entire DRAM and NAND Production for Next Yr >000660.SE

28 oct 2025, 22:45 UTC

Ganancias

SK Hynix 3Q Net KRW12.6T >000660.SE

28 oct 2025, 22:44 UTC

Ganancias

SK Hynix 3Q Rev KRW24.44T >000660.SE

28 oct 2025, 22:43 UTC

Ganancias

SK Hynix 3Q Net Profit Beat FactSet-Compiled Consensus

28 oct 2025, 22:42 UTC

Ganancias

SK Hynix 3Q Net KRW12.598T Vs. Net KRW5.753T >000660.SE

28 oct 2025, 22:40 UTC

Ganancias

SK Hynix 3Q Rev KRW24.449T Vs. KRW17.573T >000660.SE

28 oct 2025, 22:40 UTC

Ganancias

SK Hynix 3Q Oper Pft KRW11.383T Vs. Pft KRW7.030T >000660.SE

28 oct 2025, 22:22 UTC

Ganancias

Pharmaron Beijing: Higher Contributions From Clinical-Development Services Supported Results >300759.SZ

28 oct 2025, 22:22 UTC

Ganancias

Pharmaron Beijing: Higher Contributions From Laboratory Services Supported Results >300759.SZ

28 oct 2025, 22:22 UTC

Ganancias

Pharmaron Beijing 3Q Net CNY439.52M, Up 42.5% on Year >300759.SZ

28 oct 2025, 22:20 UTC

Ganancias

Pharmaron Beijing 3Q Rev CNY3.64B, Up 13.4% on Year >300759.SZ

28 oct 2025, 22:02 UTC

Ganancias

Review & Preview: Earnings Extravaganza -- Barrons.com

28 oct 2025, 21:42 UTC

Charlas de Mercado
Ganancias

Global Equities Roundup: Market Talk

28 oct 2025, 21:42 UTC

Charlas de Mercado
Ganancias

Mondelez Says Cocoa Costs Peaked Heading Into Spooky Season -- Market Talk

28 oct 2025, 21:20 UTC

Ganancias

Wal-Mart de Mexico 3Q EBITDA MXN25.27B, Up 3.3% on Year

28 oct 2025, 21:19 UTC

Ganancias

Wal-Mart de Mexico 3Q Rev MXN241.52B, Up 4.9% on Year

28 oct 2025, 21:18 UTC

Ganancias

Wal-Mart de Mexico 3Q Net MXN11.75B, Down 9.2% on Year

Comparación entre iguales

Cambio de precio

Codexis Inc previsión

Precio Objetivo

By TipRanks

143.46% repunte

Estimación a 12 Meses

Media 6.33 USD  143.46%

Máximo 11 USD

Mínimo 3 USD

De acuerdo con 5 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Codexis Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

5 ratings

3

Comprar

2

Mantener

0

Vender

Puntuación técnica

By Trading Central

2.25 / 2.53Soporte y Resistencia

Corto Plazo

Bullish Evidence

Medio plazo

Strong Bearish Evidence

Largo Plazo

Bearish Evidence

Sentimiento

By Acuity

154 / 373 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Codexis Inc

Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, the company is currently developing its proprietary ECO Synthesis(tm) manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.
help-icon Live chat